← All trials
NCT04518995
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 2, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Mar 31, 2022
- First posted
- Aug 19, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 700
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Concert PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.